Byondis reckons trastuzumab duocarmazine (also known as SYD985) is a "next-generation" anti-HER2 ADC, with an improved toxicity profile compared to rivals like Roche's Kadcyla (adotrastuzumab ...

SUZHOU, China, March 18, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that anti-HER2 ...

Enhertu is already approved as a second-line or later therapy for HER2-positive breast cancer based on the results of the ...

In a Phase I study presented at AACR's annual meeting, 71 percent of patients who hadn't received a prior anti-HER2 ADC responded to the drug.

As an anti-HER2 ADC, preliminary findings from IBI354 have demonstrated encouraging objective response rates (ORR) and disease control rates (DCR) in PROC. Furthermore, IBI354 exhibits a superior ...

However, recurrent and metastatic breast cancer still has significant unmet clinical needs. JSKN003 is an anti-HER2 biparatopic ADC developed inhouse with Alphamab's proprietary Glycan-specific ...